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Cyclophosphamide (Cy) in combination with busulfan (Bu) or total body irradiation (TBI) is the most
commonly used myeloablative conditioning regimen in patients with chronic myeloid leukemia (CML). We
used data from the Center for International Bone Marrow Transplantation Research to compare outcomes in
adults who underwent hematopoietic cell transplantation for CML in ﬁrst chronic phase after myeloablativeedgments on page 557.
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Total body irradiationconditioning with Cy in combination with TBI, oral Bu, or intravenous (i.v.) Bu. Four hundred thirty-eight
adults received human leukocyte antigen (HLA)-matched sibling grafts and 235 received well-matched
grafts from unrelated donors (URD) from 2000 through 2006. Important differences existed between the
groups in distribution of donor relation, exposure to tyrosine kinase inhibitors, and year of transplantation. In
multivariate analysis, relapse occurred less frequently among patients receiving i.v. Bu compared with TBI
(relative risk [RR], .36; P ¼ .022) or oral Bu (RR, .39; P ¼ .028), but nonrelapse mortality and survival were
similar. A signiﬁcant interaction was detected between donor relation and the main effect in leukemia-free
survival (LFS). Among recipients of HLA-identical sibling grafts, but not URD grafts, LFS was better in pa-
tients receiving i.v. Bu (RR, .53; P ¼ .025) or oral Bu (RR, .64; P ¼ .017) compared with TBI. In CML in ﬁrst
chronic phase, Cy in combination with i.v. Bu was associated with less relapse than TBI or oral Bu. LFS was
better after i.v. or oral Bu compared with TBI.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Tyrosine kinase inhibitors (TKIs) have replaced allogeneic
hematopoietic cell transplantation (HCT) as initial therapy of
patients with chronic myeloid leukemia (CML). Nevertheless,
many patients with CML eventually receive an allotransplant.
Determining the best pretransplantation conditioning
regimen is important.
Cyclophosphamide (Cy) combined with total body irra-
diation (TBI) has historically been the standard pre-
transplantation conditioning regimen [1-4]. The combination
of Cywith a ﬁxed dose of oral busulfan (BuCy) has also proven
effective in CML [5]. A randomized comparison of Cy/TBI to
BuCy in patients with CML undergoing human leukocyte
antigen (HLA)-identical sibling transplantation reported
comparable relapse, leukemia-free survival (LFS), and overall
survival (OS). BuCy was better tolerated, however, with
shorter hospitalization and less acute graft-versus-host dis-
ease (GVHD) [6]. A second randomized study reported similar
outcomes but with fewer relapses in the BuCy cohort [7].
The development of an assay for plasma Bu was initially
reported in 1983 [8], but an assay was not commercially
available until 1996 [9]. Studies of Bu kinetics revealed that
oral Bu is erratically absorbed and that oral administration of
a ﬁxed dose results in wide variations in plasma Bu levels
[10-13]. Low plasma levels are associated with increased
risks of graft failure and relapse, and high levels are associ-
ated with increased toxicity [10-12]. Dose adjustment of oral
Bu, based on plasma levels after the initial dose, decreases
the variability and may improve outcomes [14]. An intrave-
nous (i.v.) formulation of Bu was developed and its use in
patients was ﬁrst reported in 2002 [15,16]. It provides com-
plete bioavailability, much more consistent plasma levels,
less acute toxicity, and lower 100-day mortality than an oral
ﬁxed dose [15,16]. Although a retrospective study in acute
myeloid leukemia (AML) from the European Group for Blood
and Marrow Transplantation failed to show signiﬁcant dif-
ferences in outcome [17], a recent large retrospective study
in patients with AML in ﬁrst remission from the Center for
International Bone Marrow Transplant Research (CIBMTR)
reported signiﬁcantly less nonrelapse mortality (NRM) and
late relapse, and better LFS and OS with Cy in combination
with i.v., but not oral, Bu compared with TBI [18]. A recent
prospective cohort analysis in persons with myelodysplastic
syndrome, AML, and CML reported better survival after i.v.
Bu than with TBI [19].
No prospective or retrospective study has compared Cy in
combination with i.v. Bu, oral Bu, or TBI in patients with CML
in chronic phase. We used data from CIBMTR to compare
outcomes after these regimens.PATIENTS AND METHODS
Data Sources
The CIBMTR is a working group of more than 500 transplantation cen-
ters worldwide that voluntarily contribute data on allogeneic and autolo-
gous transplantations. Detailed demographic, disease, and transplantation
characteristics and outcome data are collected on a sample of registered
patients including all unrelated donor (URD) transplantations facilitated by
the National Marrow Donor Program in the United States. Observational
studies conducted by the CIBMTR are carried out with a waiver of informed
consent and in compliance with Health Insurance Portability and Account-
ability Act regulations, as determined by the institutional review board and
the privacy ofﬁcer of the Medical College of Wisconsin.
Patients
The study population consisted of all patients 18 years of age reported
to the CIBMTR who received a ﬁrst HCT with an HLA-identical sibling or
well-matched URD [20] from 2000 through 2006 for CML in ﬁrst chronic
phase after pretransplantation conditioning with Cy/TBI (single
dose 5.5 Gy, fractionated  9 Gy) or Bu (9 mg/kg) combined with Cy and
no other anticancer drugs. The data set was derived from CIBMTR
comprehensive report forms. Patients with a genetically identical twin or
cord blood donor, an ex vivo T celledepleted graft, a less than well-matched
URD, or those receiving Cy after transplantation were excluded. Data
regarding Bu pharmacokinetics (PK) were not collected.
Study Endpoints and Deﬁnitions
The primary outcome studied was OS. Patients were considered to have
an event at the time of death from any cause; survivors were censored at last
contact. NRM was deﬁned as death without evidence of leukemia recur-
rence; relapse, deﬁned by hematologic, cytogenetic, or molecular criteria,
was considered a competing event. LFS was deﬁned as time to treatment
failure (death or relapse). For relapse, NRM, and LFS, patients alive in
continuous complete remission were censored at last follow-up. Times to
neutrophil and platelet recovery were calculated as the time from trans-
plantation to achieving the ﬁrst of 3 consecutive days with neutrophils
>.5  109/L and platelets >20  109/L, 7 days from the last platelet trans-
fusion. Acute GVHD was graded according to consensus criteria, based on
the pattern of severity of abnormalities in skin, gastrointestinal tract, and
liver [21]. Chronic GVHD was diagnosed by standard criteria [22]. For he-
matopoietic recovery and GVHD, death without the event was considered a
competing event.
Statistical Methods
In univariate analysis, probabilities of LFS and OS were calculated using
the Kaplan-Meier method, with the variance estimated by Greenwood’s
formula. Hematopoietic recovery, GVHD, NRM, and relapse were estimated
using the cumulative incidence method to account for competing risks.
In multivariate analysis, a forward stepwise selection procedure was
performed using the proportional hazards Cox model for OS, LFS, NRM,
GVHD, and relapse to adjust for the following variables considered for in-
clusion in each model: age, gender, and Karnofsky performance score at
transplantation for subject-related variables; interval from diagnosis to
transplantation and TKI use before HCT for disease-related variables, and
donor-recipient gender and cytomegalovirus serological status, donor
relation and graft source, year of transplantation, antithymocyte globulin
(ATG) or alemtuzumab use, GVHD prophylaxis, and planned use of growth
factors after transplantation for transplantation-related variables. A P value
<.05 was used to select variables to enter and to retain as covariates in the
model. The proportional hazards assumption was assessed for each variable
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selected variable and the main effect.
Adjusted LFS and survival probabilities were estimated through the
direct adjusted survival curves estimation method [23]. SAS software,
version 9.3 (SAS Institute, Cary, NC) was used in all analyses.RESULTS
Demographics and Univariate Analysis
Six hundred seventy-three adults received a ﬁrst HCT
from an HLA-matched sibling (n ¼ 438) or well-matched
unrelated donor (URD; n ¼ 235) from January 1, 2000
through December 31, 2006 for CML in ﬁrst chronic phase
after myeloablative preparation with Cy combined with TBI,
oral Bu, or i.v. Bu. The median follow-up of surviving patients
is 5 years.
Characteristics of patients categorized according to pre-
transplantation conditioning regimen are described in
Table 1. Patients who received i.v. Bu were older (median age,
39 years; 42% > 40 years) than those receiving TBI (median
age, 35 years; 31% > 40 years) or oral Bu (median age,
34 years; 29% > 40 years). Eighty-three percent of patients
receiving oral Bu and 67% receiving i.v. Bu received a trans-
plant from an HLA-identical sibling compared with 36% of
those receiving TBI.
Sixty-seven percent of i.v. Bu patients, comparedwith 27%
of oral Bu and 36% of TBI patients, received at least 1 TKI
before transplantation. Nine percent of oral Bu and 13% of i.v.
Bu patients received ATG or alemtuzumab compared with
18% of those receiving TBI. Sixty-eight percent of i.v. Bu pa-
tients, compared with 37% oral Bu and 23% of TBI patients,
underwent HCT from 2004 to 2006, the last 3 years of study.
Median and interquartile range (IQR) of radiation dose was
12 Gy (IQR, 12 to 13.2 Gy) and Cy dose was 119.5 mg/kg (IQR,
98 to 120 mg/kg) for patients receiving TBI. Median Cy doses
were 119 mg/kg (IQR, 105 to 120 mg/kg) and 109 mg/kg (IQR,
98 to 120 mg/kg) for those receiving oral and i.v. Bu. Median
Cy does were identical (119 mg/kg) for patients receiving
BuCy regardless of whether the donor was an HLA-identical
sibling or unrelated. The median and IQR Bu dose were
15.7 mg/kg (IQR, 14 to 16 mg/kg) for patients receiving oral
Bu and 12 mg/kg (IQR, 10 to 13 mg/kg) for those receiving
i.v. Bu.
Neutrophil recovery at 28 days was similar among the
groups, but platelet recovery at 28 days occurred in a higher
proportion of oral (75%; 95% conﬁdence interval [CI], 71% to
80%) or i.v. Bu (77%; 95% CI, 68% to 85%) patients than in those
receiving TBI (64%; 95% CI, 58% to 70%; P ¼ .009) (Table 2).
The incidences of hepatic veno-occlusive disease and inter-
stitial pneumonia at 100 days, and NRM, LFS, and OS at
5 years did not differ signiﬁcantly among the 3 groups
(Table 2).
The incidence of relapse (hematologic, cytogenetic, or
molecular) at 5 years was 17% (95% CI,12% to 23%) for TBI, 17%
(95% CI, 12% to 22%) for oral Bu, and 7% (95% CI, 2% to 14%) for
i.v. Bu (P ¼ .014). Univariate analyses of speciﬁc clinical out-
comes and covariates are summarized in Supplemental
Table S1. Thirty-eight patients (4 for no hematopoietic re-
covery, 5 for graft failure, 7 for relapse, and 22 for whom the
indication was missing) underwent either a second HCT
(n ¼ 11) or donor lymphocyte infusion (n ¼ 27). Of these 38
patients, 26 are still alive.Multivariate Analysis
Relapse occurred signiﬁcantly less frequently among pa-
tients receiving i.v. Bu compared with those receiving TBI(relative risk [RR], .36; 95% CI, .15 to .86; P ¼ .022) or oral Bu
(RR, .39; 95% CI, .17 to .90; P ¼ .028). NRM and OS were
similar among the groups (Table 3).
The interaction term between donor relation (HLA-iden-
tical sibling, URD) and the main effect variable (oral Bu
versus i.v. Bu versus TBI) was signiﬁcant for acute GVHD
grade 3, chronic GVHD, and LFS. The results for each donor
relation are presented separately based on the multivariate
models that included donor relation as a covariate as well as
the signiﬁcant interaction term. Among patients receiving
grafts from HLA-identical siblings, the incidences of acute
GVHD grade 3 and chronic GVHD were similar for all 3
groups. For patients with URD, however, compared with TBI,
the incidence of acute GVHD grade 3 was higher in those
receiving oral Bu (RR, 1.76; 95% CI, 1.02 to 3.04; P ¼ .043) or
i.v. Bu (RR, 2.62; 95% CI, 1.34 to 5.12; P ¼ .005). The incidence
of chronic GVHD among patients with unrelated donors was
higher for those receiving oral (RR, 2.73; 95% CI, 1.82 to 4.10;
P < .0001), but not i.v., Bu compared with TBI.
LFS was signiﬁcantly better among recipients of HLA-
identical sibling (Figure 1), but not among recipients from
URD, grafts receiving oral (RR, .64; 95% CI, .44 to .92; P¼ .017)
or i.v. Bu (RR, .53; 95% CI, .31 to .92; P ¼ .025) compared with
TBI. To determine whether administration of higher radia-
tion doses might contribute to inferior outcomes with TBI,
the TBI cohort was divided into those receiving standard
(<12.5 Gy) and high-dose TBI in a separate multivariate
analysis (Table 4). Use of i.v. Bu remained associated with
lower relapse (RR, .38; 95% CI, .16 to .94; P¼ .037) and, among
recipients of related grafts, better LFS (RR, .55; 95% CI, .31 to
.98; P ¼ .044) than standard-dose TBI.
LFS was worse for recipients of URD grafts who received
oral, but not i.v., Bu compared with TBI (RR, 1.69; 95% CI, 1.11
to 2.56; P ¼ .014).The use of a TKI before HCT was not
adversely associated with any of the reported outcomes and
was associated with better LFS. (RR, .69; 95% CI, .53 to .92;
P ¼ .01).
DISCUSSION
Although transplantation is no longer ﬁrst-line treatment
for CML in ﬁrst chronic phase, many patients who are
resistant to or intolerant of TKI continue to undergo the
procedure [24-26]. CIBMTR registration retrieval for the
United States alone identiﬁed 120 allogeneic trans-
plantations, of whom 113 recipients were 18 years of age,
for CML in ﬁrst chronic phase in 2012 and 2013 (Wael Saber,
personal communication). Our retrospective analysis shows
that, in patients with chronic phase CML, relapse occurred
signiﬁcantly less often among those who received i.v. Bu
compared with those who received oral Bu or TBI, regardless
of whether patients received standard or high doses of TBI.
LFS was better among those receiving HLA-identical sibling
grafts who received i.v. or oral Bu compared with those who
received TBI, including when the analysis was limited to
those patients who received standard TBI doses.
OS, however, did not differ among the groups. The effec-
tiveness of TKIs and donor lymphocyte infusions in extend-
ing survival after relapse in CML [27] and the limited
(5 years) follow-up of the present study probably account for
similar OS despite the differences in relapse and LFS.
Nevertheless, cure is the ultimate goal of HCT in CML. The
lower incidence of relapse and better LFS with i.v. Bu
(compared with TBI) support its use in patients receiving
HLA-identical sibling grafts. LFS after HLA-identical sibling
grafts was also superior to TBI in patients receiving oral Bu. It
Table 1
Characteristics of Patients
Characteristics Cy TBI Oral BuCy i.v. BuCy Overall P Value
No. of patients 222 354 97
No. of centers 75 68 47
Patient-related characteristics
Age, median (range), yr 35 (18-59) 34 (18-59) 39 (18-61) .018
18-30 73 (33) 136 (38) 28 (29) .167
31-40 80 (36) 116 (33) 28 (29)
41-50 47 (21) 75 (21) 27 (28)
>50 22 (10) 27 (8) 14 (14)
Sex .293
Male 145 (65) 211 (60) 56 (58)
Karnofsky performance score at transplantation .142
<90% 19 (9) 21 (6) 11 (11)
90% 193 (87) 326 (92) 83 (86)
Missing 10 (5) 7 (2) 3 (3)
Disease-related characteristics
Time from diagnosis to transplantation, median (range), mo 10 (3-79) 9 (2-96) 10 (2-149) .813
TKI use before transplantation <.001
No 143 (64) 258 (73) 32 (33)
Yes 79 (36) 96 (27) 65 (67)
Transplantation-related characteristics
Donor-recipient sex match .503
M-M 102 (46) 139 (39) 37 (38)
F-M 43 (19) 72 (20) 19 (20)
M-F 44 (20) 70 (20) 24 (25)
F-F 33 (15) 73 (21) 17 (18)
Donor relation <.001
HLA-identical sibling 80 (36) 293 (83) 65 (67)
Well-matched URD 142 (64) 61 (17) 32 (33)
Donor-recipient CMV serological status <.001
þ/þ 75 (34) 74 (21) 26 (27)
þ/ 56 (25) 197 (56) 35 (36)
/þ 36 (16) 26 (7) 13 (13)
/ 49 (22) 45 (13) 17 (18)
Missing 6 (3) 12 (3) 6 (6)
HLA-identical sibling donor age, median (range), yr 37 (13-70) 34 (3-65) 40 (20-61) <.001
Unrelated donor age, median (range), yr 35 (19-61) 33 (20-46) 38 (21-51) .063
Graft type <.001
Bone marrow 146 (66) 168 (47) 49 (51)
Peripheral blood 76 (34) 186 (53) 48 (49)
Conditioning regimen
Bu dose, median (range), mg/kg e 16 (10-25) 12 (9-17) e
Cy/TBI (nonfrac 550-750) 9 (4) 0 0
Cy/TBI (nonfrac 800-1200) 4 (2) 0 0
Cy/TBI (frac 900-1170) 13 (6) 0 0
Cy/TBI (frac 1200-1300) 123 (55) 0 0
Cy/TBI (frac 1320-1395) 40 (18) 0 0
Cy/TBI (frac 1400-1500) 33 (15) 0 0
ATG or alemtuzumab use 0.004
Yes 41 (18) 32 (9) 13 (13)
No 181 (82) 322 (91) 84 (87)
GVHD prophylaxis <.001
TAC þ MMF  others 6 (3) 1 (<1) 4 (4)
TAC þ MTX  others (except MMF) 49 (22) 23 (6) 44 (45)
TAC þ others (except MTX, MMF) 6 (3) 2 (<1) 0
TAC alone 2 (<1) 0 1 (1)
CSA þ MMF  others (except TAC) 6 (3) 4 (1) 2 (2)
CSA þ MTX  others (except TAC, MMF) 140 (63) 307 (87) 40 (41)
CSA þ others (except TAC, MTX, MMF) 5 (2) 3 (<1) 1 (1)
CSA alone 6 (3) 4 (1) 1 (1)
Other 0 2 (<1) 3 (3)
Missing 2 (<1) 8 (2) 1 (1)
Growth factors given after transplantation .299
No 172 (77) 253 (71) 72 (74)
Yes 49 (22) 101 (29) 25 (26)
Missing 1 (<1) 0 0
Year of transplantation <.001
2000 81 (36) 93 (26) 9 (9)
2001 45 (20) 44 (12) 8 (8)
2002 28 (13) 59 (17) 5 (5)
2003 15 (7) 26 (7) 10 (10)
2004 14 (6) 43 (12) 28 (29)
2005 21 (9) 54 (15) 19 (20)
2006 18 (8) 35 (10) 18 (19)
Median follow-up of survivors, range, mo 72 (2-127) 56 (2-129) 59 (3-119)
M indicates male; F, female; CMV, cytomegalovirus; nonfrac, nonfractionated; frac, fractionated; TAC, tacrolimus; MMF, mycophenolate mofetil; MTX, meth-
otrexate; CSA, cyclosporine.
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Table 2
Univariate Analysis
Outcomes Cy TBI
Probability
(95% CI)
Oral BuCy
Probability
(95% CI)
IV BuCy
Probability
(95% CI)
Overall
P Values
Neutrophil recovery
NEval 222 354 97
At 28 d 92 (88-95) 91 (88-94) 95 (90-98) .391
Platelet recovery
NEval 221 346 96
At 28 d 64 (58-70) 75 (71-80) 77 (68-85) .009
At 100 d 90 (85-93) 93 (90-95) 96 (91-99) .103
Acute GVHD (II-IV)
NEval 222 352 97
At 100 d 56 (50-63) 43 (39-49) 46 (37-56) .014
Acute GVHD (III-IV)
NEval 222 354 97
At 100 d 24 (19-30) 20 (16-24) 26 (18-35) .290
Hepatic veno-occlusive disease
NEval 222 354 97
At 100 d 5 (2-9) 9 (7-13) 6 (2-12) .17
Interstitial pneumonia
NEval 222 354 97
At 100 d 9 (5-13) 5 (3-8) 4 (1-9) .22
Chronic GVHD
NEval 216 348 95
At 5 yr 55 (48-61) 62 (57-68) 67 (57-76) .082
NRM
NEval 216 350 95
At 1 yr 25 (20-31) 20 (16-24) 16 (9-24) .142
At 3 yr 31 (25-38) 24 (20-29) 22 (14-31) .139
At 5 yr 31 (25-38) 25 (21-30) 36 (25-48) .119
Relapse
NEval 216 350 95
At 5 yr 17 (12-23) 17 (12-22) 7 (2-14) .014
LFS
NEval 216 350 95 .102
At 1 yr 67 (60-73) 74 (69-78) 80 (72-88) .031
At 3 yr 55 (48-62) 62 (57-68) 74 (64-82) .006
At 5 yr 52 (45-59) 58 (52-64) 57 (45-69) .384
OS
NEval 222 354 97 .196
At 1 yr 74 (68-80) 80 (75-84) 84 (76-91) .118
At 3 yr 67 (60-73) 74 (69-78) 77 (68-85) .097
At 5 yr 66 (59-72) 72 (67-77) 61 (50-73) .152
N Eval indicates number evaluable.
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patients [18]. The oral formulation has been largely displaced
by the i.v. formulation [28], but PK-based oral dosing mightTable 3
Relative Risks and 95% CI of a Multivariate Analysis
Oral BuCy versus
TBI RR (95% CI)
IV B
TBI R
aGVHD II-IV* .87 (.66-1.13) .81
aGVHD III-IV for HLA sibsy .71 (.42-1.18) .89
aGVHD III-IV for URDy 1.76 (1.02-3.04) 2.62
cGVHD for HLA sibsz 1.22 (.85-1.74) 1.31
cGVHD for URDz 2.73 (1.82-4.10) 1.52
LFS for HLA sibsx .64 (.44-.92) .53
LFS for URDx 1.69 (1.11-2.56) 1.32
Relapsek .94 (.61-1.45) .36
NRM{ 1.17 (.81-1.68) 1.26
OS# 1.15 (.81-1.62) 1.19
aGVHD indicates acute GVHD; sibs, siblings; cGVHD, chronic GVHD.
Bold typeface indicates P value <.05.
Other signiﬁcant factors in the multivariate model include:
* Graft type, donor relation.
y Donor relation, year of transplantation.
z Donor relation, sex match, graft type, ATG, or alemtuzumab use.
x Donor relation, recipient age, TKI.
k None.
{ Donor relation, recipient age, graft type, year of transplantation.
# Year of transplantation, recipient age, donor relation.yield similar results. This was not speciﬁcally addressed in
the present study. Important differences in LFS between i.v.
Bu and TBI were not identiﬁed for recipients of URD grafts
with the available sample size in this study.
In AML, studies of Cy combined with ﬁxed-dose oral Bu
have reported some disadvantages, including higher relapse
rates, compared with TBI [29,30]. In contrast, compared with
TBI, i.v. Bu was associated with lower relapse rates beyond
1 year, less NRM, and better LFS and survival in patients with
AML in complete remission [18]. It would seem that the
advantage of i.v. Bu might be magniﬁed in CML, where oral
ﬁxed-dose Bu showed advantages over TBI, including less
toxicity [6] and relapse [7], and favorable results were re-
ported with dose-adjusted oral Bu [14]. Notably, NRM was
comparatively low in the present study in the i.v. Bu group
relative to the TBI cohort at 1 and 3 years, but it was similar at
5 years. A higher proportion of patients receiving i.v. Bu who
were alive at 3 years subsequently died from NRM compared
with those receiving TBI, but no clear pattern in the cause of
death emerged. In particular, only 1 death attributed to
chronic GVHD occurred beyond 3 years in the i.v. Bu cohort
(data not shown). We also have no precise explanation for
the higher incidence of acute GVHD grade III with Bu
compared with TBI in recipients of URD grafts; however, TBI
patients were more likely to have received marrow and ATG
or alemtuzumab. These data contrast with reports of less
GVHD with Bu in CML [6] and AML [17], although those
studies were performed with HLA-identical sibling donors.
Importantly, the use of a TKI before HCT did not adversely
inﬂuence the outcomes reported and was associated with
better LFS. These results support a previous report that
imatinib use before HCT did not adversely inﬂuence trans-
plantation outcomes [31]. The signiﬁcantly lower incidence
of relapse with i.v. Bu and better LFS with i.v. (or oral) Bu
compared with TBI in recipients of HLA-identical related
grafts were present regardless of whether TKI use was
considered in the multivariate model.
There are, of course, limitations to this retrospective
analysis. First, it is not known why individual patients
received speciﬁc preparative regimens. Second, there were
important differences between the groups, especially in the
distribution of related and unrelated donors, TKI exposure,
and year when transplantation was performed. MultivariateuCy versus
R (95% CI)
Oral Bucy versus i.v.
BuCy RR (95% CI)
Overall P
(.57-1.14) 1.07 (.77-1.49) .405
(.44-1.81) .79 (.43-1.47) .37
(1.34-5.12) .67 (.33-1.36) .01
(.83-2.05) .93 (.65-1.33) .47
(.94-2.47) 1.79 (1.04-3.08) <.0001
(.31-.92) 1.19 (.72-1.98) .025
(.75-2.32) 1.28 (.71-2.32) .046
(.15-.86) 2.58 (1.11-6.03) .067
(.78-2.03) .93 (.60-1.45) .576
(.75-1.88) .97 (.63-1.48) .679
Figure 1. Adjusted probabilities of LFS according to preparative regimen for recipients of grafts from HLA-identical sibling (adjusted covariates: TKI use before HCT,
recipient age).
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but the relatively few patients in the i.v. Bu arm, particularly
those receiving grafts from URD, limits the effectiveness of
that approach. In addition, over the course of the study, the
use of molecular detection of relapse became more wide-
spread. The application of more sensitive techniques to
detect relapse, however, would likely result in earlier
detection in patients undergoing transplantation in the later
years of study, potentially leading to an underestimation of
the difference in relapse with i.v. Bu. Also, data were not
collected for PK studies and dose adjustment, which is re-
ported to affect outcomes with i.v [32]. as well as oral Bu
[33]. We were, therefore, unable to analyze the potential
beneﬁt of PK-directed dosing in patients receiving oral or
i.v. Bu.
Absent results of a randomized trial, the association of
i.v. Bu with lower relapses rates in ﬁrst chronic phase CML
patients, and better LFS compared with TBI among re-
cipients of HLA-identical sibling grafts, favors its use in that
setting.Table 4
Relative Risks and 95% CI of a Multivariate Analysis (TBI Dose Divided into Standar
Oral BuCy versus
TBI (1250) RR
(95% CI)
IV BuCy versus
TBI (1250) RR
(95% CI)
TBI (>1250
versus TBI
(1250) RR
(95% CI)
aGVHD II-IV* .82 (.61-1.09) .76 (.53-1.1) .84 (.58-1.
aGVHD III-IV for HLA sibsy .87 (.47-1.6) 1.10 (.5-2.41) 1.96 (.81-4.
aGVHD III-IV for URDy 2.04 (1.09-3.8) 3.05 (1.46-6.35) 1.44 (.73-2.
cGVHD for HLA sibsz 1.17 (.78-1.76) 1.26 (.77-2.06) .87 (.41-1.
cGVHD for URDz 2.07 (1.35-3.18) 1.14 (.69-1.89) .46 (.28-.7
LFS for HLA sibsx .66 (.43-.99) .55 (.31-.98) 1.1 (.56-2.
LFS for URDx 1.96 (1.23-3.13) 1.53 (.84-2.8) 1.48 (.89-2.
Relapsek .99 (.6-1.63) .38 (.16-.94) 1.17 (.58-2.
NRM{ 1.27 (.84-1.9) 1.36 (.82-2.26) 1.26 (.77-2.
OS# 1.26 (.86-1.85) 1.3 (.8-2.12) 1.31 (.83-2.
Bold typeface indicates P value <.05.
Other signiﬁcant factors in the multivariate model include:
* Graft type, donor relation.
y Donor relation, year of transplantation.
z Donor relation, sex match, graft type, ATG, or alemtuzumab use.
x Donor relation, recipient age, TKI.
k None.
{ Donor relation, recipient age, graft type, year of transplantation.
# Year of transplantation, recipient age, donor relation.ACKNOWLEDGMENTS
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